NovoCure：我为何不看好第二季度财报后的涨势 (NASDAQ:NVCR)
· seekingalpha.com
NovoCure 股票维持“持有”评级：第二季度营收增长 16%，EBITDA 指引有所改善，但现金生成能力滞后。点击阅读我的分析。
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...